Browse FMOD

Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF13855 Leucine rich repeat
PF01462 Leucine rich repeat N-terminal domain
Function

Affects the rate of fibrils formation. May have a primary role in collagen fibrillogenesis (By similarity).

> Gene Ontology
 
Biological Process GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006790 sulfur compound metabolic process
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007181 transforming growth factor beta receptor complex assembly
GO:0007409 axonogenesis
GO:0018146 keratan sulfate biosynthetic process
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0030203 glycosaminoglycan metabolic process
GO:0042339 keratan sulfate metabolic process
GO:0042340 keratan sulfate catabolic process
GO:0043062 extracellular structure organization
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0061564 axon development
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3656244: Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
R-HSA-3656225: Defective CHST6 causes MCDC1
R-HSA-3656243: Defective ST3GAL3 causes MCT12 and EIEE15
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022854: Keratan sulfate biosynthesis
R-HSA-2022857: Keratan sulfate degradation
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FMOD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FMOD and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18323802Chronic Lymphocytic LeukemiaPromote immunity (T cell function); essential for immunotherapyA significant increase of specific cytotoxic CD8+ T lymphocytes against the leukemia-associated antigens RHAMM or fibromodulin was detected in four patients after DC vaccination.
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FMOD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FMOD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.4570.0667
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.6050.234
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5960.678
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5440.198
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8950.616
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0990.966
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2940.697
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0570.973
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7160.696
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2220.905
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6140.815
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4360.0292
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FMOD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FMOD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FMOD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FMOD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FMOD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FMOD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FMOD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFMOD
Namefibromodulin
Aliases SLRR2E; fibromodulin proteoglycan; FM; KSPG fibromodulin; collagen-binding 59 kDa protein; keratan sulfate p ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FMOD collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.